Insulin-induced amyloidosis is a rare skin-related complication of insulin therapy. However, it remains unclear whether insulin-induced amyloidosis affects insulin uptake and thus glycemic control in diabetic patients. For this reason, Professor Terumasa Nagase and his team from the Department of Endocrinology and Metabolism, Ibaraki Medical Center, Tokyo Medical University, Japan, conducted a study to investigate the effects of insulin-induced amyloidosis on glycemic control, insulin requirement, and insulin absorption in diabetic patients. The results of the study were published in the May 2014 issue of The American Journal of Medicine. In this study, Prof. Nagase et al. recruited seven diabetic patients with insulin-induced amyloidosis at the Ibaraki Medical Center, and studied the clinical characteristics and insulin therapy of these seven patients. Furthermore, four of the patients were given insulin injections at the site of insulin-induced amyloidosis and at the normal site, and the serum insulin levels after insulin injections were compared to determine the insulin uptake at the site. This study found that when patients developed insulin-induced amyloidosis, their mean glycated hemoglobin level was 9.3% and their mean daily insulin dose was 57 units. Professor Nagase also found that insulin absorption at the site of insulin-induced amyloidosis was 34% of that at the normal site. This study suggests that insulin-induced amyloidosis can lead to poor glycemic control and increased insulin requirements in patients due to impaired insulin uptake.